Mebeverine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mebeverine
Accession Number
DB12554
Description

Mebeverine has been investigated for the treatment of Irritable Bowel Syndrome and Post-cholecystectomy Gastrointestinal Spasms.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 429.557
Monoisotopic: 429.251523231
Chemical Formula
C25H35NO5
Synonyms
  • Mebeverina
  • Mebeverine
  • Mebeverinum
External IDs
  • BRN 2783282

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideAcetazolamide may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.
AcetophenazineAcetophenazine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.
AcipimoxThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Mebeverine.
AclidiniumThe risk or severity of adverse effects can be increased when Mebeverine is combined with Aclidinium.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Mebeverine.
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.
Alendronic acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Mebeverine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Mebeverine.
AlimemazineAlimemazine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.
AlloinThe therapeutic efficacy of Alloin can be decreased when used in combination with Mebeverine.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Mebeverine hydrochloride15VZ5AL4JN2753-45-9PLGQWYOULXPJRE-UHFFFAOYSA-N
International/Other Brands
Colofac / Duspatal / Duspatalin / Rudakol
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ARLUY DUOMebeverine hydrochloride (200 mg) + Simethicone (300 mg)Capsule, liquid filledOral2018-07-06Not applicableColombia flag

Categories

ATC Codes
A03AA04 — Mebeverine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as p-methoxybenzoic acids and derivatives. These are benzoic acids in which the hydrogen atom at position 4 of the benzene ring is replaced by a methoxy group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
P-methoxybenzoic acids and derivatives
Alternative Parents
M-methoxybenzoic acids and derivatives / Amphetamines and derivatives / Benzoic acid esters / Dimethoxybenzenes / Phenylpropanes / Phenoxy compounds / Anisoles / Benzoyl derivatives / Alkyl aryl ethers / Aralkylamines
show 7 more
Substituents
Alkyl aryl ether / Amine / Amino acid or derivatives / Amphetamine or derivatives / Anisole / Aralkylamine / Aromatic homomonocyclic compound / Benzoate ester / Benzoyl / Carboxylic acid derivative
show 20 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
7F80CC3NNV
CAS number
3625-06-7
InChI Key
VYVKHNNGDFVQGA-UHFFFAOYSA-N
InChI
InChI=1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3
IUPAC Name
4-{ethyl[1-(4-methoxyphenyl)propan-2-yl]amino}butyl 3,4-dimethoxybenzoate
SMILES
CCN(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)C(C)CC1=CC=C(OC)C=C1

References

General References
Not Available
PubChem Compound
4031
PubChem Substance
347828778
ChemSpider
3891
RxNav
29410
ChEBI
91514
ChEMBL
CHEMBL282121
Wikipedia
Mebeverine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentCancer, Bladder / Incontinence / Incontinence, Daytime Urinary / Incontinence, Nighttime Urinary / Oncology / Orthotopic Neobladder1
4CompletedTreatmentIrritable Bowel Syndrome (IBS)1
3RecruitingTreatmentIrritable Bowel Syndrome (IBS)1
Not AvailableCompletedNot AvailablePost-cholecystectomy Gastrointestinal Spasms1
Not AvailableCompletedTreatmentIncontinence / Urinary Bladder Cancer / Urinary Incontinence (UI)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Capsule, liquid filledOral
Tablet, sugar coatedOral
CapsuleOral
Capsule, extended releaseOral200 mg
Tablet, coatedOral100 mg
Capsule, extended releaseOral
SyrupOral
SuspensionOral
Tablet, coatedOral
Tablet, film coatedOral
Tablet, delayed releaseOral
Capsule, delayed releaseOral
TabletOral
CapsuleOral200 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0029 mg/mLALOGPS
logP4.87ALOGPS
logP4.89ChemAxon
logS-5.2ALOGPS
pKa (Strongest Basic)10.31ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area57.23 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity123.54 m3·mol-1ChemAxon
Polarizability49.66 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0000900000-211570923a386119fb40
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001j-0700900000-99c57564f3fc24c545e0
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-006t-0900000000-c0682f422d00560d08ba
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-0900000000-2e05532c5e033b444833
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-1900000000-932bf2e1c980e01c0e84
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00ea-0900300000-a95ec1fe9eb9355e870d

Drug created on October 20, 2016 22:50 / Updated on February 21, 2021 18:53